Imricor benefits as elective surgery resumed in German

2021-03-09 02:04:32 (AET) by Ring Zhang   421


Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has announced today that one of its collaboration partners in Europe, the Helios Leipzig Heart Centre, has resumed elective surgery.

Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has announced today that one of its collaboration partners in Europe, the Helios Leipzig Heart Centre, has resumed elective surgery.

text

The German medical centre has signed a purchase agreement with Imricor in September 2020 to perform their ablation procedures using Imricor’s products.

While general lockdowns across Germany have been extended until 28 March, elective procedures at the Leipzig Heart Centre are no longer prohibited, according to Professor Gerhard Hindricks, Head of Electrophysiology at the Heart Centre.

This is the second time a IMR collaborative partner has announced the restart of elective procedures this quarter, following the announcement in February this year regarding surgery restriction lifted in Maastricht University Medical Centre+ in the Netherlands.

text

A bit intro about Imricor

Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
心脏消融手术设备提供商IMR和澳新医疗设备分商RHCG签署协议

医疗设备公司Imricor Medical Systems (ASX: IMR)与悉尼医疗产品分销公司Regional Health Care Group Pty Ltd签订产品分销协议。根据协议,RHCG成为Imricor消耗品(订阅产品)的独家分销商,以及Imricor核心设备的澳洲和新西兰非独家分销商。此外,RGCH还将帮助Imricor产品在澳大利亚和新西兰获得必要的监管批准,团队预计将于2021年底获得首批批准。

相关文章

cover
心脏消融手术设备提供商IMR和澳新医疗设备分商RHCG签署协议

医疗设备公司Imricor Medical Systems (ASX: IMR)与悉尼医疗产品分销公司Regional Health Care Group Pty Ltd签订产品分销协议。根据协议,RHCG成为Imricor消耗品(订阅产品)的独家分销商,以及Imricor核心设备的澳洲和新西兰非独家分销商。此外,RGCH还将帮助Imricor产品在澳大利亚和新西兰获得必要的监管批准,团队预计将于2021年底获得首批批准。

cover
Imricor signed distribution agreement to facilitate sales in Australia and NZ

Imricor Medical Systems (ASX: IMR) signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.